Johnson & Johnson (J&J) has closed the previously announced acquisition of Abiomed, a medical device technology company, for an enterprise value of around $16.6bn, in a move to strengthen its MedTech portfolio. The acquisition of Abiomed, which was announced in November 2022, is expected to add heart recovery solutions to the MedTech portfolio of Johnson […]
Johnson & Johnson (J&J) has agreed to acquire Abiomed, a NASDAQ-listed cardiovascular medical technology provider, in an all-cash deal valued at approximately $16.6 billion. The proposed acquisition is expected to further diversify and expand Johnson & Johnson MedTech (JJMT) portfolio into the heart failure and recovery segment through Abiomed’s Impella heart pump platform. Joaquin Duato […]
Johnson & Johnson (JNJ) has announced plans to carve out its consumer health business into a new publicly traded company to focus on its biopharma and medical device businesses. According to the US healthcare conglomerate, the move will create two global majors that are better placed to deliver enhanced health outcomes for patients and consumers, […]